--Notice of Intent to Award Sole Source

The U.S. Army Medical Research Acquisition Activity plans to award a sole source contract to the law firm Baker and Botts, LLP, for legal services concerning the patent prosecution of RIID 99-29 Botulinum, covering all serotypes. This work includes handling U.S. and international patent applications linked to research conducted at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). The decision to continue with Baker and Botts, LLP is based on the firm's longstanding involvement and expertise in the ongoing patent prosecution efforts related to RIID 99-29 Botulinum, making a follow-on contract advantageous for the government. There is no public solicitation process associated with this award, emphasizing the sole source nature of the contract. The point of contact for this action is Contract Specialist Randal Barnett, who can be reached via email. The contract highlights the government's reliance on established legal counsel to ensure continuity and effectiveness in managing critical patent protections arising from military medical research.